Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

Slides:



Advertisements
Similar presentations
Orkhon Tsogtbaatar, ID: April 18, 2012
Advertisements

YAP and TAZ (Yes-Associated Protein and Transcriptional coactivator with PDZ Binding Motif) Multiple Cancers Lucy Laws My name is Lucy and I am going.
Volume 76, Issue 9, Pages (November 2009)
Nithya Krishnamurthy, Razelle Kurzrock  Cancer Treatment Reviews 
The Wnt signaling pathway in cancer
by Edward E. Morrisey Circulation Research Volume 109(6):
Eph-Ephrin Bidirectional Signaling in Physiology and Disease
Ian M. Adcock, PhD, Kittipong Maneechotesuwan, MD, Omar Usmani, MBBS 
Pathogen-Mediated Posttranslational Modifications: A Re-emerging Field
IRS-1: Auditing the effectiveness of mTOR inhibitors
A CRTCal Link between Energy and Life Span
HSF1 in Translation Cancer Cell
AMPK-Dependent Phosphorylation of ULK1 Induces Autophagy
Stopping the Clock with MYC
Is Hepatitis C Virus Carcinogenic?
Signaling molecules as therapeutic targets in allergic diseases
Killing Tumors by Keeping Ras and PI3′ Kinase Apart
Yorkie and Scalloped: Partners in Growth Activation
Fixing a Hole Where the Ras Gets In
Integrins and Mutant p53 on the Road to Metastasis
Integrins and Mutant p53 on the Road to Metastasis
Methed-Up FOXOs Can't In-Akt-ivate
Gating Immunity and Death at the Nuclear Pore Complex
Volume 29, Issue 3, Pages (March 2016)
Gonadotropin Signaling in the Ovary
Identification of TOR Signaling Complexes
Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers  Yu Chen, Charles L. Sawyers  Cancer Cell  Volume.
Designing New Cellular Signaling Pathways
Transcriptional Addiction in Cancer
A New Twist in Smad Signaling
Spectraplakins: The Cytoskeleton's Swiss Army Knife
Volume 76, Issue 9, Pages (November 2009)
IRS-1: Auditing the effectiveness of mTOR inhibitors
Hippo Pathway Key to Ploidy Checkpoint
From Cell Structure to Transcription: Hippo Forges a New Path
Keeping Transcriptional Activators under Control
The RAS/MAPK Axis Gets Stressed Out
Long Noncoding RNA in Hematopoiesis and Immunity
Pushing Back: Wound Mechanotransduction in Repair and Regeneration
AKT/PKB Signaling: Navigating the Network
Circadian Clock: Time for a Phase Shift of Ideas?
Hippo: Hungry, Hungry for Melanoma Invasion
A New FOXO Pathway Required for Leukemogenesis
CDK Inhibitors: Cell Cycle Regulators and Beyond
Proteins Kinases: Chromatin-Associated Enzymes?
Caspases and Kinases in a Death Grip
p38δ and PKD1: Kinase Switches for Insulin Secretion
Volume 49, Issue 1, Pages 1-3 (January 2013)
Blinded by the Light: The Growing Complexity of p53
John D. Gordan, Craig B. Thompson, M. Celeste Simon  Cancer Cell 
Metabolic Homeostasis: HDACs Take Center Stage
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
CAMTA in Cardiac Hypertrophy
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
Wnt/β-Catenin Signaling in Development and Disease
Modes of p53 Regulation Cell
The Expanding Cosmos of Nuclear Receptor Coactivators
Ethylene Prunes Translation
Alexander Kiani, Anjana Rao, Jose Aramburu  Immunity 
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Hippo Signaling Goes Long Range
Shared Principles in NF-κB Signaling
GPC5 Gene and Its Related Pathways in Lung Cancer
Mst Out and HCC In Cancer Cell
Notch signaling from tumor cells: A new mechanism of angiogenesis
Matthew D. Weitzman, Jonathan B. Weitzman  Cell Host & Microbe 
Interplay between YAP/TAZ and Metabolism
Volume 13, Issue 3, Pages (March 2008)
PTEN and p53: Who will get the upper hand?
No Driver behind the Wheel? Targeting Transcription in Cancer
Presentation transcript:

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer Fa-Xing Yu, Bin Zhao, Kun-Liang Guan  Cell  Volume 163, Issue 4, Pages 811-828 (November 2015) DOI: 10.1016/j.cell.2015.10.044 Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 Inhibition of YAP/TAZ Transcriptional Coactivators by LATS1/2 (Left) When Hippo signaling is off, YAP/TAZ enter the nucleus, compete with VGLL4 for TEADs, and recruit other factors to induce gene transcription. YAP/TAZ may bind proximal promoters or distal enhancers of target genes to induce transcription. (Right) When Hippo signaling is on, YAP/TAZ are phosphorylated by LATS1/2 on multiple sites, resulting in interaction with 14-3-3 and cytoplasmic retention; phosphorylation also leads to YAP/TAZ poly-ubiquitination and degradation. VGLL4 interacts with TEADs and represses target gene transcription. Cell 2015 163, 811-828DOI: (10.1016/j.cell.2015.10.044) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 2 Regulation of the Hippo Pathway in Drosophila The Hippo pathway is regulated by cell-adhesion molecules (Ed), determinants of cell polarity (Crb, Fat/Ds, Scrib complex), and mechanical cues (spectrin, F-actin, or cellular tension). In addition, Hpo is regulated by Tao, salt-induced kinase (Sik), Ras-associated factor (Rassf), striatin-interacting phosphatase and kinase (STRIPAK) complex; Wts is regulated by Zyxin (Zyx) and Jub; Yki is regulated by WW-domain-binding protein 2 (Wbp2), Hipk, and multiple ankyrin repeats single-KH domain (Mask) (refer to Varelas, 2014). Arrows, blunt ends, and dashed lines indicate activation, inhibition, and indirect regulation, respectively. Cell 2015 163, 811-828DOI: (10.1016/j.cell.2015.10.044) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 3 Regulation of the Hippo Pathway in Mammals The Hippo pathway is regulated by diverse signals: (1) determinants of cell polarity and cell-cell junctions, such as SCRIB, which interacts with MST1/2 and LATS1/2, AMOT, PTPN14, and α-catenin, which can sequester YAP/TAZ to cell junctions; (2) mechanical cues, such as stiffness, cell contact, cell geometry, and cell attachment status that regulate the Hippo pathway by modulating activity of Rho GTPases, remodeling the actin cytoskeleton, or altering cellular tension; both apical and basolateral spectrin networks may function as sensors for mechanical cues in Hippo pathway regulation; (3) soluble factors, especially ligands for GPCRs, regulate LATS1/2 likely through Rho GTPases and actin dynamics; (4) metabolic status, such as cellular energy and oxygen stress, also regulate Hippo signaling; many other proteins such as protein phosphatase 2A (PP2A), protein phosphatase 1 (PP1), WBP2, CDK1, MASK, and HIPK can also regulate activities of different Hippo pathway components (refer to Varelas, 2014). Arrows, blunt ends, and dashed lines indicate activation, inhibition, and indirect regulation, respectively. Cell 2015 163, 811-828DOI: (10.1016/j.cell.2015.10.044) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 4 Therapeutic Targeting of the Hippo Pathway (A) Potential roles of YAP/TAZ activity in tissue development and diseases. A confined window of YAP/TAZ activity is required for normal tissue development and homeostasis. (B) Strategies for targeting YAP/TAZ activity. Inhibitors for MST1/2, MAP4K4, and LATS1/2 can activate YAP/TAZ. YAP/TAZ-TEAD interaction may be disrupted by small molecules directly (Verteporfin) or AMPK activators (Metformin). Small molecules inhibiting Rho-family GTPases or ROCK can indirectly activate LATS1/2, leading to YAP/TAZ inhibition. Cell 2015 163, 811-828DOI: (10.1016/j.cell.2015.10.044) Copyright © 2015 Elsevier Inc. Terms and Conditions